Metraipolis › archive › dc_22e278d2ca9f

Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis — Europe PMC PMID:40131983

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40131983
DOI
10.1371/journal.pone.0320189
License (as archived)
solo-consultazione
Archived
2026-10-08T04:38:32.382Z
SHA-256 of the archived text
1044a0f5f9a1453ccb0be10d57cfaff92ce14c371d8607fbc0e4dca80edfb0a1
Stable URL of this page
https://metraipolis.com/documento/dc_22e278d2ca9f

How to cite

Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis — Europe PMC PMID:40131983 — Europe PMC (en), https://europepmc.org/article/MED/40131983 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_22e278d2ca9f (Metraipolis archive dc_22e278d2ca9f, sha256 1044a0f5f9a1453ccb0be10d57cfaff92ce14c371d8607fbc0e4dca80edfb0a1)
BibTeX
@misc{dc22e278d2ca9f,
  title = {Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis — Europe PMC PMID:40131983},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40131983},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_22e278d2ca9f; sha256 1044a0f5f9a1453ccb0be10d57cfaff92ce14c371d8607fbc0e4dca80edfb0a1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40131983. Agents can read the archived copy with the MCP tool read_document.